Revelation Biosciences Inc. is a clinical-stage life sciences company. It focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company's product pipeline includes REVTx-99, REVTx-200 and REVDx-501. Revelation Biosciences Inc., formerly known as Petra Acquisition Inc., is based in NEW YORK.
Info & Links
CEO
James Rolke
Headquarters
4660 LAJOLLA VILLAGE DRIVE, SUITE 100 SAN DIEGO, CA 92122, UNITED STATES
Revelation Biosciences, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
1.10M
Enterprise Value
-5.44M
Enterprise Value/EBITDA(ttm)
0.64
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
0.44
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
0.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
0.00%
Return on Equity(ttm)
-193.51%
Return on Invested Capital(ttm)
-880.96%
Return on Assets(ttm)
-84.00%
Income Statement
Revenue(ttm)
0.00
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
0.00
EBITDA(ttm)3
-8.52M
Net Income Available to Common(ttm)
-15.52M
Diluted EPS(ttm)
-268.16
Share Statistics
Beta (5Y Monthly)
0.19
52-Week Change
-91.27%
S&P 500 52-Week Change
18.16%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
268.28K
Dividend Yield
0.00%
Float4
268.00K
% Held by Insiders
0.06%
% Held by Institutions
12.80%
Balance Sheet
Total Cash(mrq)
6.54M
Total Cash Per Share(mrq)
24.38
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
1.64%
Quick Ratio(mrq)
1.64%
Book Value Per Share(mrq)
9.97
Cash Flow
Operating Cash Flow Per Share(ytd)
-87.01
Free Cash Flow(ytd)
-14.61M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.